Faruqi and Faruqui, LLP Logo
Share this page

Acorda Therapeutics Inc. (ACOR)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Acorda Therapeutics Inc. (“Acorda” or the “Company”) (NasdaqGS:ACOR).

The investigation focuses on whether the Company and its executives violated federal securities laws in connection with Acorda’s Ampyra patents.  

On March 31, 2017, the Company announced that U.S. District Judge Leonard Stark of the United States District Court for the District of Delaware invalidated the Company’s four patents under U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,007,826 (the ‘826 patent), 8,440,703 (the ‘703 patent), and 8,354,437 (the ‘437 patent), which pertain to Ampyra. 

On this news, Acorda’s share price fell from $26.75 per share on March 30, 2017 to a closing price of $21.00 on March 31, 2017—a $5.75 or a 21.5% drop.

Take Action

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Acorda’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Acorda Therapeutics Inc. (ACOR)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 04/07/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.